{"id":"adjuvant-systemic-chemotherapy","safety":{"commonSideEffects":[{"rate":null,"effect":"Myelosuppression (neutropenia, anemia, thrombocytopenia)"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Alopecia"},{"rate":null,"effect":"Mucositis"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Peripheral neuropathy"},{"rate":null,"effect":"Cardiotoxicity (depending on agents used)"}]},"_chembl":{"chemblId":"CHEMBL4650400","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Adjuvant chemotherapy is a treatment strategy rather than a single drug, involving the systemic administration of chemotherapeutic agents following surgery or primary treatment. The goal is to target micrometastatic disease and improve overall survival by reducing the risk of cancer recurrence. The specific mechanism depends on the chemotherapy regimen used, which may include alkylating agents, antimetabolites, or other cytotoxic compounds.","oneSentence":"Adjuvant systemic chemotherapy uses cytotoxic drugs administered after primary cancer treatment to eliminate residual cancer cells and reduce recurrence risk.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:44:13.856Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Adjuvant treatment of various solid tumors following primary surgical resection"}]},"trialDetails":[{"nctId":"NCT03387553","phase":"EARLY_PHASE1","title":"HER2 Directed Dendritic Cell Vaccine During Neoadjuvant Therapy of HER2+Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2018-06-06","conditions":"Breast Cancer, Breast Cancer Female, Breast Cancer, Male","enrollment":31},{"nctId":"NCT01272037","phase":"PHASE3","title":"Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2011-02-28","conditions":"Breast Ductal Carcinoma In Situ, Invasive Breast Carcinoma, Multicentric Breast Carcinoma","enrollment":5018},{"nctId":"NCT02758951","phase":"PHASE2, PHASE3","title":"Perioperative Systemic Therapy for Isolated Resectable Colorectal Peritoneal Metastases","status":"ACTIVE_NOT_RECRUITING","sponsor":"Koen Rovers","startDate":"2017-06-01","conditions":"Colorectal Neoplasm, Colorectal Cancer, Colorectal Neoplasms Malignant","enrollment":358},{"nctId":"NCT05871099","phase":"PHASE3","title":"Laparoscopic Gastrectomy With D2 Lymphadenectomy Combined With Hyperthermic Intraperitoneal Chemotherapy (HIPEC) or Not","status":"RECRUITING","sponsor":"The Affiliated Hospital of Qingdao University","startDate":"2022-11-20","conditions":"Gastric Cancer","enrollment":616},{"nctId":"NCT07136493","phase":"NA","title":"Circulating Tumor DNA Based Minimal Residual Disease Detection for Patients With Early-Stage Breast Cancer","status":"SUSPENDED","sponsor":"City of Hope Medical Center","startDate":"2026-05-12","conditions":"Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8","enrollment":350},{"nctId":"NCT06632327","phase":"PHASE3","title":"Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer","status":"RECRUITING","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2024-12-11","conditions":"Resectable Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8","enrollment":1100},{"nctId":"NCT07053085","phase":"PHASE2","title":"A Study of Surgery and Radiotherapy in People With Breast Cancer","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2025-09-17","conditions":"Metastatic Breast Cancer, HER2-positive Breast Cancer","enrollment":162},{"nctId":"NCT07421141","phase":"PHASE2","title":"De-escalation of Neoadjuvant Treatment (Paclitaxel + HP) in Early HER2+ Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Medical Research Radiological Centre of the Ministry of Health of Russia","startDate":"2023-09-01","conditions":"Breast Cancer, HER2-positive Breast Cancer, Early Breast Cancer","enrollment":186},{"nctId":"NCT07429487","phase":"NA","title":"Assessment of Adherence to Remotely Monitored Physical Activity Tracked on a Smartwatch, and Its Impact on Reducing Fatigue 3 Months After Adjuvant Chemotherapy for Cancer","status":"NOT_YET_RECRUITING","sponsor":"Centre Antoine Lacassagne","startDate":"2026-06-15","conditions":"Breast Cancer, Colorectal Cancer, Ovarian Adenocarcinoma","enrollment":98},{"nctId":"NCT07429643","phase":"PHASE2, PHASE3","title":"Endoscopic Ultrasound-Guided Loco-regional Chemotherapy Injection as Adjuvant Therapy for Locally Advanced Pancreatic Cancer.","status":"NOT_YET_RECRUITING","sponsor":"Assiut University","startDate":"2026-04-15","conditions":"Locally Advanced Pancreatic Cancer","enrollment":20},{"nctId":"NCT06290687","phase":"PHASE2","title":"Partial Cystectomy & Extended Pelvic Lymph Node Dissection With SOC Perioperative Systemic Therapy","status":"RECRUITING","sponsor":"Case Comprehensive Cancer Center","startDate":"2025-02-18","conditions":"Malignant Neoplasm of Bladder, Muscle Invasive Bladder Carcinoma","enrollment":40},{"nctId":"NCT06384560","phase":"PHASE1, PHASE2","title":"Neoadjuvant Triple Therapy for (Borderline) Resectable Pancreatic Cancer (PREOPANC-5)","status":"RECRUITING","sponsor":"Amsterdam UMC, location VUmc","startDate":"2024-09-23","conditions":"Localized Pancreatic Adenocarcinoma, Borderline Resectable Pancreatic Adenocarcinoma, Resectable Pancreatic Adenocarcinoma","enrollment":66},{"nctId":"NCT07407920","phase":"PHASE2","title":"Ph2 Study for Optimization of Adjunct Systemic Therapy in HER2+ Patients, MolecularPCR Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2025-10-09","conditions":"Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Early Stage HER2-Positive Breast Carcinoma","enrollment":120},{"nctId":"NCT06107920","phase":"PHASE3","title":"Neoadjuvant Chemotherapy for Obstructive Colon cancER First Treated by cOlostomy","status":"RECRUITING","sponsor":"University Hospital, Rouen","startDate":"2024-05-07","conditions":"Colon Cancer","enrollment":232},{"nctId":"NCT07233928","phase":"NA","title":"Breast Cancer Organelle Properties and Protein Expression Atlas in the Three Immunohistochemical Subtypes of Breast Cancers","status":"RECRUITING","sponsor":"Institut Claudius Regaud","startDate":"2026-02-06","conditions":"Early Breast Cancer, Metastatic Breast Cancer","enrollment":1050},{"nctId":"NCT05415215","phase":"PHASE3","title":"A Study to Evaluate Patient Preference for Home Administration of Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Administration in Participants With Early or Locally Advanced/Inflammatory HER2-Positive Breast Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2022-07-05","conditions":"Early Breast Cancer, Locally Advanced Breast Cancer, Inflammatory Breast Cancer","enrollment":346},{"nctId":"NCT05333874","phase":"EARLY_PHASE1","title":"CIPHER Study: Pilot Study to Study the Role of ctDNA in Triple Negative and HER2 Positive Early Stage","status":"ACTIVE_NOT_RECRUITING","sponsor":"Rutgers, The State University of New Jersey","startDate":"2022-04-06","conditions":"Breast Cancer, Early-Onset","enrollment":34},{"nctId":"NCT04700124","phase":"PHASE3","title":"Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-Eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2021-04-21","conditions":"Bladder Cancer","enrollment":808},{"nctId":"NCT01815359","phase":"PHASE2","title":"ICARuS Post-operative Intraperitoneal Chemotherapy (EPIC) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) After Optimal Cytoreductive Surgery (CRS) for Neoplasms of the Appendix, Colon or Rectum With Isolated Peritoneal Metastasis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2013-03","conditions":"Appendix Cancer, Colorectal Cancer","enrollment":292},{"nctId":"NCT04990895","phase":"NA","title":"A Research Study to Collect Patient Reported Outcomes Using Electronic Surveys","status":"TERMINATED","sponsor":"AHS Cancer Control Alberta","startDate":"2022-03-30","conditions":"Colorectal Cancer, Breast Cancer","enrollment":8},{"nctId":"NCT07290972","phase":"","title":"Compliance to Cervical Cancer Chemoradiation Guidelines: A Multicentric Implementation Audit and Resource Assessment Initiative of National Cancer Grid of India","status":"RECRUITING","sponsor":"Tata Memorial Hospital","startDate":"2021-02-01","conditions":"Cervical Cancer Screening, Gynecologic Cancers, Treatment Compliance","enrollment":618},{"nctId":"NCT06833502","phase":"PHASE2","title":"Phase II Study of Systemic Screening in Pathologic Node Positive Breast Cancer","status":"RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2025-02-24","conditions":"Breast Cancer, Node-positive Breast Cancer","enrollment":120},{"nctId":"NCT07266025","phase":"PHASE2","title":"Adebrelimab Combined With Induction Chemotherapy or SHR-8068 for Mismatch Repair-Deficient/Microsatellite Instability-High (dMMR/MSI-H) Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma：A Randomized, Non-comparative Phase 2 Study","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Zhongshan Hospital","startDate":"2026-01-30","conditions":"Gastric Adenocarcinoma, Gastroesophageal Adenocarcinoma, Mismatch Repair Deficient or MSI-High Solid Tumors","enrollment":30},{"nctId":"NCT06481813","phase":"NA","title":"Prospective, Longitudinal Biocollection in Thoracic Oncology, Including Newly Diagnosed Lung Cancer Patients","status":"RECRUITING","sponsor":"Nantes University Hospital","startDate":"2024-12-10","conditions":"Lung Cancer, Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma","enrollment":730},{"nctId":"NCT07335770","phase":"","title":"Cardiac Magnetic Resonance for Diagnosis, Treatment Guidance and Prognosis of Cardiac Masses (CMR)","status":"ENROLLING_BY_INVITATION","sponsor":"Minjie Lu","startDate":"2008-01-01","conditions":"Cardiac Masses","enrollment":2000},{"nctId":"NCT06155279","phase":"PHASE2","title":"Induction Chemo+Immunotherapy in Resectable Epithelioid and Biphasic Pleural Mesothelioma (CHIMERA Study)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Istituto Oncologico Veneto IRCCS","startDate":"2024-11-06","conditions":"Pleural Mesothelioma","enrollment":41},{"nctId":"NCT06210776","phase":"","title":"A Study to Assess the Effectiveness of Trastuzumab Deruxtecan in Chinese Breast Cancer Patients (REFRESH)","status":"RECRUITING","sponsor":"Daiichi Sankyo","startDate":"2024-01-15","conditions":"HER2-positive Breast Cancer, HER2-low Breast Cancer, Breast Cancer","enrollment":800},{"nctId":"NCT02511106","phase":"PHASE3","title":"AZD9291 Versus Placebo in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy.","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2015-10-21","conditions":"Stage IB-IIIA Non-small Cell Lung Carcinoma","enrollment":682},{"nctId":"NCT07304258","phase":"PHASE2","title":"A Prospective, Phase II Clinical Study of HIPEC Combined With NIPS and Tislelizumab Conversion Therapy for Gastric Cancer With Peritoneal Metastasis With Positive Cytology Alone or PCI Score ≤10","status":"NOT_YET_RECRUITING","sponsor":"Hebei Medical University","startDate":"2025-12-12","conditions":"Gastric Cancer Peritoneal Metastases","enrollment":30},{"nctId":"NCT04711824","phase":"PHASE1, PHASE2","title":"Study of Stereotactic Radiosurgery With Olaparib Followed by Durvalumab and Physician's Choice Systemic Therapy in Subjects With Breast Cancer Brain Metastases","status":"RECRUITING","sponsor":"Colette Shen","startDate":"2022-03-09","conditions":"Breast Cancer, Brain Metastases, Adult","enrollment":41},{"nctId":"NCT05860296","phase":"PHASE1, PHASE2","title":"Testing Experimental Anti-cancer Drug SLC-391 With an Approved Immunotherapy Drug, Pembrolizumab, for Advanced Lung Cancers","status":"TERMINATED","sponsor":"SignalChem Lifesciences Corporation","startDate":"2023-05-31","conditions":"Lung Cancer, Nonsmall Cell, Lung Cancer Stage IV, Lung Cancer Metastatic","enrollment":36},{"nctId":"NCT07241793","phase":"PHASE2","title":"Phase II Study of Trastuzumab Rezetecan or in Combination With Adebrelimab in HER2-Expressing Locally Advanced or Metastatic Urothelial Carcinoma (la/mUC)","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2025-11-20","conditions":"Urothelial Carcinoma, Advanced Urothelial Carcinoma, Urothelial Carcinoma Recurrent","enrollment":96},{"nctId":"NCT04727242","phase":"PHASE2","title":"CytoreductiveSurgery & HIPEC w/Gemcitabine+Chemotherapy w/Dacarbazine in Uterine Leiomyosarcoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Stanford University","startDate":"2021-01-28","conditions":"LMS - Leiomyosarcoma, Uterine Leiomyosarcoma","enrollment":17},{"nctId":"NCT05088395","phase":"NA","title":"Analysis of Circulating Tumor mArkers in Blood 4 - ALCINA 4","status":"RECRUITING","sponsor":"Institut Curie","startDate":"2022-05-19","conditions":"Cancer","enrollment":2050},{"nctId":"NCT04733118","phase":"PHASE2","title":"Chemotherapy-Free pCR-Guided Strategy With Trastuzumab-pertuzumab and T-DM1 in HER2-positive Early Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"MedSIR","startDate":"2021-08-05","conditions":"Early Breast Cancer","enrollment":393},{"nctId":"NCT04363801","phase":"PHASE2","title":"A Study of DKN-01 in Combination With Tislelizumab ± Chemotherapy in Patients With Gastric or Gastroesophageal Cancer","status":"TERMINATED","sponsor":"Leap Therapeutics, Inc.","startDate":"2020-07-29","conditions":"Gastric Cancer, Gastric Adenocarcinoma, GastroEsophageal Cancer","enrollment":247},{"nctId":"NCT05116072","phase":"PHASE1, PHASE2","title":"Efficacy and Safety of TPIAT for Resectable Adenocarcinoma of the Pancreas Region at High Risk of Postoperative Fistula","status":"RECRUITING","sponsor":"University Hospital, Lille","startDate":"2022-02-20","conditions":"Adenocarcinoma of the Pancreas, Adenocarcinoma of the Duodenum, Ampullary Adenocarcinoma","enrollment":36},{"nctId":"NCT04722523","phase":"PHASE1","title":"A Study of Cemiplimab With Chemotherapy and Immunotherapy in People With Head and Neck Cancer","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2021-01-20","conditions":"Head and Neck Cancer, Head Cancer, Head Cancer Neck","enrollment":40},{"nctId":"NCT07010939","phase":"","title":"A Study of Treatment-Related Toxicities and Quality of Life After Local Therapy in Chinese Breast Cancer Patients","status":"RECRUITING","sponsor":"FangYi","startDate":"2025-04-07","conditions":"Breast Neoplasms, Quality of Life (QOL), Toxicities","enrollment":3000},{"nctId":"NCT07007182","phase":"PHASE2","title":"Conversion Therapy Plus Surgery and Radiotherapy for Retroperitoneal Nodal Metastases in Gastric Cancer","status":"NOT_YET_RECRUITING","sponsor":"Jinbo Yue","startDate":"2025-10-01","conditions":"Gastric Adenocarcinoma, Stomach Neoplasms","enrollment":54},{"nctId":"NCT05417737","phase":"","title":"Patients Referred to the Chronic Pain Unit for Palliative Treatment With Ozone Therapy Between 2022 and 2025","status":"RECRUITING","sponsor":"Bernardino Clavo, MD, PhD","startDate":"2022-06-15","conditions":"Radiation Toxicity, Chemotherapeutic Toxicity, Chemotherapy-induced Peripheral Neuropathy","enrollment":105},{"nctId":"NCT00766142","phase":"PHASE2","title":"Chemotherapy and Cetuximab in Patients Undergoing Surgery for Peritoneal Carcinomatosis From Colorectal Cancer","status":"TERMINATED","sponsor":"Institut Bergonié","startDate":"2007-05-01","conditions":"Colorectal Cancer, Primary Peritoneal Cavity Cancer","enrollment":18},{"nctId":"NCT07133490","phase":"PHASE2","title":"INTERACT Stomach-II","status":"NOT_YET_RECRUITING","sponsor":"Erasmus Medical Center","startDate":"2025-10-01","conditions":"Peritoneal Metastases From Gastric Cancer","enrollment":49},{"nctId":"NCT06839092","phase":"PHASE3","title":"Prophylactic PIPAC in Patients With High-risk Colorectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Jeremy Meyer","startDate":"2026-01","conditions":"Colorectal Cancer Control and Prevention, Colorectal Cancer, Colorectal Cancer Stage II","enrollment":160},{"nctId":"NCT03348150","phase":"PHASE3","title":"Gastrectomy + Cytoreductive Surgery + HIPEC for Gastric Cancer With Peritoneal Dissemination.","status":"ACTIVE_NOT_RECRUITING","sponsor":"The Netherlands Cancer Institute","startDate":"2017-10-01","conditions":"Stomach Neoplasm, Peritoneal Carcinomatosis","enrollment":102},{"nctId":"NCT06427252","phase":"PHASE2","title":"The Efficacy and Safety of HIPEC Combined With PD-1 and SOX Chemotherapy for the Translational Treatment of GC or EGJC With PM","status":"ACTIVE_NOT_RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2024-05-31","conditions":"Gastric Cancer, Metastatic","enrollment":50},{"nctId":"NCT06914440","phase":"PHASE2","title":"Neoadjuvant SBRT Followed by Nab-Paclitaxel Combined With Toripalimab in HR+/HER2- Breast Cancer","status":"RECRUITING","sponsor":"Xijing Hospital","startDate":"2025-06-05","conditions":"Breast Cancer","enrollment":27},{"nctId":"NCT06990737","phase":"PHASE2","title":"Phase 2 Pragmatic Trial of Sentinel Lymph Node Biopsy (SLNB) in Patients With Clinically Node-Negative (cN0), High-Risk Cutaneous Squamous Cell Carcinoma (cSCC) of the Head and Neck","status":"RECRUITING","sponsor":"University of California, Davis","startDate":"2025-06-25","conditions":"Cutaneous Squamous Cell Carcinoma of the Head and Neck, Clinically Node-Negative (cN0), High-Risk Cutaneous Squamous Cell Carcinoma (cSCC) of the Head and Neck","enrollment":24},{"nctId":"NCT06719362","phase":"PHASE1","title":"A Clinical Trial to Evaluate the Safety, Tolerability and Clinical Efficacy of M3T01 Monotherapy and in Combination With Pembrolizumab and Other Systemic Therapies","status":"RECRUITING","sponsor":"Providence Health & Services","startDate":"2025-06-17","conditions":"Advanced Solid Tumors","enrollment":110},{"nctId":"NCT01564056","phase":"PHASE3","title":"Adjuvant Systemic Treatment for (ER)-Positive HER2-negative Breast Carcinoma in Women Over 70 According to Genomic Grade (GG): Chemotherapy + Endocrine Treatment Versus Endocrine Treatment","status":"ACTIVE_NOT_RECRUITING","sponsor":"UNICANCER","startDate":"2012-04-12","conditions":"Breast Cancer","enrollment":1989},{"nctId":"NCT03645928","phase":"PHASE2","title":"Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors","status":"RECRUITING","sponsor":"Iovance Biotherapeutics, Inc.","startDate":"2019-05-07","conditions":"Metastatic Melanoma, Squamous Cell Carcinoma of the Head and Neck, Non-small Cell Lung Cancer","enrollment":245},{"nctId":"NCT06991491","phase":"PHASE2","title":"Ivonescimab With GnP and SBRT in Patients With Metastatic Pancreatic Cancer (WGOG-PAN 004)","status":"NOT_YET_RECRUITING","sponsor":"West China Hospital","startDate":"2025-06-01","conditions":"Pancreatic Cancer","enrollment":29},{"nctId":"NCT02998385","phase":"PHASE3","title":"Chemo-radiotherapy Versus Radiotherapy in the Treatment of Salivary Glands and Nasal Tumors (IMRT or Protontherapy)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Groupe Oncologie Radiotherapie Tete et Cou","startDate":"2017-01-20","conditions":"HNSCC","enrollment":342},{"nctId":"NCT06946901","phase":"PHASE2","title":"The Safety and Effectiveness of Hyperthermic Intraperitoneal Chemotherapy Combined With Intravenous Chemotherapy for Peritoneal Metastatic Pancreatic Cancer, a Phase II Clinical Trial","status":"RECRUITING","sponsor":"Shanghai Zhongshan Hospital","startDate":"2025-04-03","conditions":"Hyperthermic Intraperitoneal Chemotherapy, Peritoneal Metastatic Pancreatic Cancer","enrollment":90},{"nctId":"NCT03475121","phase":"PHASE3","title":"Treatment Protocol for Non-Metastatic Unilateral Retinoblastoma","status":"COMPLETED","sponsor":"Hospital JP Garrahan","startDate":"2018-01-01","conditions":"Unilateral Retinoblastoma","enrollment":84},{"nctId":"NCT06685887","phase":"PHASE2","title":"A Clinical Study Evaluating the Efficacy of Systemic Chemotherapy and Immune Checkpoint Inhibitors Combined With Hyperthermic Intraperitoneal Chemotherapy in the Treatment of Gastric Cancer Patients With Peritoneal Metastasis","status":"RECRUITING","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2025-02-15","conditions":"Gastric Cancer","enrollment":34},{"nctId":"NCT04474964","phase":"NA","title":"Focal Radiotherapy Plus Low Dose Craniospinal Irradiation Followed by Adjuvant Chemotherapy in WNT Medulloblastoma.","status":"RECRUITING","sponsor":"Tata Memorial Centre","startDate":"2020-08-13","conditions":"Medulloblastoma, WNT-activated","enrollment":30},{"nctId":"NCT04517214","phase":"PHASE2","title":"Comparing Chemotherapy With/Without Toripalimab For Primary Metastatic Nasopharyngeal Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fudan University","startDate":"2020-11-01","conditions":"Nasopharyngeal Carcinoma","enrollment":100},{"nctId":"NCT00059930","phase":"PHASE1","title":"Adjuvant Hepatic Arterial Infusion and Combination Chemotherapy in Treating Patients With Resectable Hepatic Metastases From Colorectal Cancer","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2003-01","conditions":"Colorectal Cancer, Metastatic Cancer","enrollment":38},{"nctId":"NCT00200200","phase":"PHASE2","title":"Hepatic Arterial Infusion With Floxuridine and Dexamethasone Combination With Chemotherapy With/Without Bevacizumab for Hepatic Metastases From Colorectal Cancer","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2004-11-19","conditions":"Hepatic Metastases, Colon Cancer, Rectal Cancer","enrollment":73},{"nctId":"NCT04022616","phase":"","title":"Myeloid-Derived Suppressor Cell Function in Breast Cancer Patients","status":"RECRUITING","sponsor":"Ohio State University Comprehensive Cancer Center","startDate":"2010-06-04","conditions":"Breast Cancer","enrollment":99},{"nctId":"NCT06660446","phase":"NA","title":"Exercise During Chemotherapy Treatment As Adjuvant Program in Patients with Lymphoma: EDONOLA Study.","status":"RECRUITING","sponsor":"Biogipuzkoa Health Research Institute","startDate":"2024-10-08","conditions":"Lymphoma","enrollment":180},{"nctId":"NCT04158141","phase":"PHASE3","title":"Testing the Addition of Targeted Radiation Therapy to Surgery and the Usual Chemotherapy Treatment (Pemetrexed and Cisplatin [or Carboplatin]) for Stage I-IIIA Malignant Pleural Mesothelioma","status":"TERMINATED","sponsor":"NRG Oncology","startDate":"2020-01-29","conditions":"Pleural Biphasic Mesothelioma, Pleural Epithelioid Mesothelioma, Stage I Pleural Malignant Mesothelioma AJCC v8","enrollment":16},{"nctId":"NCT06352567","phase":"","title":"Symptoms Associated with Chemotherapy-Induced Peripheral Neuropathy","status":"COMPLETED","sponsor":"Izmir Bakircay University","startDate":"2024-01-18","conditions":"Chemotherapy-induced Peripheral Neuropathy, Breast Cancer, Breast Cancer Female","enrollment":74},{"nctId":"NCT05313191","phase":"NA","title":"Prospective Evaluation of Pencil Beam Scanning Proton Therapy for Previously Irradiated Tumors","status":"RECRUITING","sponsor":"The New York Proton Center","startDate":"2022-01-24","conditions":"CNS Cancer, Head and Neck Cancer, GI Cancer","enrollment":1800},{"nctId":"NCT03761914","phase":"PHASE1, PHASE2","title":"Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers","status":"COMPLETED","sponsor":"Sellas Life Sciences Group","startDate":"2019-09-30","conditions":"Acute Myelogenous Leukemia, Ovarian Cancer, Colorectal Cancer","enrollment":26},{"nctId":"NCT02124421","phase":"PHASE2","title":"HOT: HIPEC in Ovarian Cancer as Initial Treatment","status":"ACTIVE_NOT_RECRUITING","sponsor":"Mercy Medical Center","startDate":"2014-04","conditions":"Stage III Ovarian Cancer, Stage IV Ovarian Cancer, Epithelial Ovarian Cancer","enrollment":32},{"nctId":"NCT02494973","phase":"PHASE2, PHASE3","title":"Postoperative Hepatic Arterial Chemotherapy in High-risk Patients as Adjuvant Treatment After Resection of Colorectal Liver Metastases","status":"COMPLETED","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2015-05-26","conditions":"Colorectal Cancer","enrollment":104},{"nctId":"NCT02040142","phase":"PHASE2","title":"HIPEC for Peritoneal Carcinomatosis","status":"COMPLETED","sponsor":"Albert Einstein College of Medicine","startDate":"2011-11","conditions":"Peritoneal Carcinomatosis, Colorectal Cancer, Appendiceal Cancer","enrollment":51},{"nctId":"NCT06631066","phase":"NA","title":"Effect of Neoadjuvant Chemoradiation on Pathologic Complete Response Rates in Locally Advanced Breast Cancer Patients","status":"COMPLETED","sponsor":"National Cancer Institute, Egypt","startDate":"2021-10-20","conditions":"Breast Cancer Female","enrollment":160},{"nctId":"NCT02866149","phase":"NA","title":"Analysis of Circulating Tumor Markers in the Blood (ALCINA)","status":"COMPLETED","sponsor":"Institut Curie","startDate":"2015-07","conditions":"Cancer","enrollment":682},{"nctId":"NCT02969122","phase":"NA","title":"Treatment Strategy for Stage IV Gastric Cancer with Positive Peritoneal Cytology As the Only Non-curable Factor","status":"TERMINATED","sponsor":"Peking University","startDate":"2016-11","conditions":"Stomach Neoplasm","enrollment":59},{"nctId":"NCT04135586","phase":"NA","title":"Effects of a Physical Exercise Intervention During Neoadjuvant Chemotherapy in Women With Breast Cancer","status":"RECRUITING","sponsor":"Universidad Europea de Madrid","startDate":"2020-01-01","conditions":"Physical Exercise","enrollment":80},{"nctId":"NCT06371586","phase":"PHASE2","title":"Neo-Sequence 2：NCT Plus Anti-angiogenesis Therapy and Immunotherapy for LADGC","status":"RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2024-03-01","conditions":"Gastric Cancer, Diffuse Type Carcinoma","enrollment":67},{"nctId":"NCT06366945","phase":"PHASE2","title":"Tirelizumab in Combination With Carboplatin and Polymeric Micellar Paclitaxel for Neoadjuvant Therapy in cN+ HNSCC","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2024-04-20","conditions":"Head and Neck Squamous Cell Carcinoma, Head and Neck Cancer, HNSCC","enrollment":85},{"nctId":"NCT06295094","phase":"PHASE2","title":"The Efficacy of PIPAC and Minimally Invasive Radical Resection in High-risk Gastric Cancer Patients.","status":"NOT_YET_RECRUITING","sponsor":"Odense University Hospital","startDate":"2024-09","conditions":"Gastric Cancer, Chemotherapy, Adjuvant, Peritoneal Metastases","enrollment":264},{"nctId":"NCT03500874","phase":"PHASE3","title":"Adjuvant Systemic Chemotherapy With or Without HAI-FUDR in Patients With Resected CRLM","status":"TERMINATED","sponsor":"Sun Yat-sen University","startDate":"2018-05-28","conditions":"Colorectal Cancer, Liver Metastases, HAI","enrollment":92},{"nctId":"NCT06154590","phase":"","title":"Anastrozole Adjuvant Trial - Study of Anastrozole Compared to NOLVADEX (Tamoxifen Citrate) for Adjuvant Treatment of Early Breast Cancer Clinical Studies), Adjunct Cytotoxic Chemotherapy and Malignant Joint Tumor","status":"NOT_YET_RECRUITING","sponsor":"DR. DIANE CHISESI NFS. MD. PHD.","startDate":"2024-07","conditions":"Metastatic Breast Cancer, Tumor, Muscle Neoplasms","enrollment":100},{"nctId":"NCT04932031","phase":"","title":"Risk Prediction of Taxane Chemotherapy-Induced Peripheral Neuropathy","status":"TERMINATED","sponsor":"Sapere Bio","startDate":"2022-05-25","conditions":"Breast Cancer, Chemotherapy-induced Peripheral Neuropathy, Aging","enrollment":123},{"nctId":"NCT03253107","phase":"","title":"Predicting Biomarker of Gastric Cancer Chemotherapy Response","status":"UNKNOWN","sponsor":"Kyungpook National University Hospital","startDate":"2015-11-30","conditions":"Gastric Cancer, Chemotherapy Effect, Predictive Cancer Model","enrollment":800},{"nctId":"NCT01106898","phase":"PHASE2","title":"Cyclophosphamide and Paclitaxel With or Without Trastuzumab in Stage I-II Breast Cancer Who Have Undergone Surgery","status":"COMPLETED","sponsor":"University of Nebraska","startDate":"2010-03-24","conditions":"Stage IA Breast Cancer, Stage IB Breast Cancer, Stage IIA Breast Cancer","enrollment":112},{"nctId":"NCT05916755","phase":"","title":"Predictive Biomarkers of Response to Checkpoint Inhibitors in Triple Negative Breast Cancer: a Multiomics Platform","status":"RECRUITING","sponsor":"Vall d'Hebron Institute of Oncology","startDate":"2023-01-13","conditions":"Triple Negative Breast Cancer","enrollment":100},{"nctId":"NCT04072107","phase":"PHASE2","title":"EPstein-barr Virus DNA Response to Systemic Therapy for Treatment Adaptation in High Risk NPC (EP-STAR)","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2020-06-01","conditions":"Nasopharyngeal Carcinoma","enrollment":110},{"nctId":"NCT02974556","phase":"PHASE3","title":"Proactive Management of Endoperitoneal Spread in Colonic Cancer","status":"UNKNOWN","sponsor":"University of Roma La Sapienza","startDate":"2024-03-01","conditions":"Colon Cancer, Intraperitoneal Rectal Cancer","enrollment":140},{"nctId":"NCT05541146","phase":"PHASE2","title":"Intraperitoneal Chemotherapy in Gastric Cancer With Peritoneal Carcinomatosis","status":"UNKNOWN","sponsor":"Instituto do Cancer do Estado de São Paulo","startDate":"2022-06-01","conditions":"Gastric Cancer, Peritoneal Carcinomatosis","enrollment":30},{"nctId":"NCT03718260","phase":"NA","title":"PSMA-PET Registry for Recurrent Prostate Cancer","status":"UNKNOWN","sponsor":"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","startDate":"2018-09-27","conditions":"Recurrent Prostate Cancer","enrollment":3070},{"nctId":"NCT03043807","phase":"PHASE2","title":"A Study of Definitive Therapy to Treat Prostate Cancer After Prostatectomy","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2017-02-22","conditions":"Prostate Cancer","enrollment":26},{"nctId":"NCT02449837","phase":"","title":"Investigation of Circulating Tumor Cells From Cancer Patients Undergoing Radiation Therapy","status":"COMPLETED","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2014-05","conditions":"Circulating Tumor Cells","enrollment":162},{"nctId":"NCT05497739","phase":"PHASE2","title":"Intraperitoneal Chemotherapy Guided by the Detection of DNA in Peritoneal Lavage Fluid in Patients With Gastric Cancer","status":"UNKNOWN","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2022-06-28","conditions":"Gastric Cancer","enrollment":68},{"nctId":"NCT02716974","phase":"PHASE2","title":"A Study of Definitive Therapy to Treat Prostate Cancer","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2016-06","conditions":"Prostate Cancer","enrollment":26},{"nctId":"NCT05285332","phase":"NA","title":"Classified Treatment Strategy for De-novo Metastatic Breast Cancer After Systemic Adjuvant Therapy","status":"NOT_YET_RECRUITING","sponsor":"Changhai Hospital","startDate":"2022-08-01","conditions":"Breast Neoplasms, Treatment, Metastatic Breast Cancer","enrollment":362},{"nctId":"NCT02850874","phase":"PHASE2","title":"HIPEC as Neoadjuvant Treatment for Resectable Pancreatic Adenocarcinoma","status":"WITHDRAWN","sponsor":"Wake Forest University Health Sciences","startDate":"2016-02","conditions":"Pancreatic Neoplasms, Pancreatic Adenocarcinoma","enrollment":""},{"nctId":"NCT00308516","phase":"PHASE2","title":"5-Fluorouracil, Bevacizumab, and Radiation Followed by Modified FOLFOX6 and Bevacizumab in Stage II/III Rectal Cancer","status":"COMPLETED","sponsor":"SCRI Development Innovations, LLC","startDate":"2006-03","conditions":"Rectal Cancer, Cancer of the Rectum, Colorectal Cancer","enrollment":66},{"nctId":"NCT00193206","phase":"PHASE2","title":"Neo-adjuvant Gemcitabine, Epirubicin, ABI-007 (GEA) in Locally Advanced or Inflammatory Breast Cancer","status":"COMPLETED","sponsor":"SCRI Development Innovations, LLC","startDate":"2005-09","conditions":"Breast Cancer","enrollment":123},{"nctId":"NCT02231086","phase":"PHASE3","title":"Adjuvant HIPEC in High Risk Colon Cancer","status":"COMPLETED","sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","startDate":"2015-03","conditions":"Colorectal Neoplasms, Peritoneal Neoplasms","enrollment":204},{"nctId":"NCT02249013","phase":"PHASE2","title":"Short-course HIPEC in Advanced Epithelial Ovarian Cancer","status":"COMPLETED","sponsor":"Professor Fernando Figueira Integral Medicine Institute","startDate":"2015-02","conditions":"Ovarian Cancer","enrollment":15},{"nctId":"NCT03986463","phase":"","title":"CIrculating Tumour DNA in Lung Cancer (CITaDeL): Optimizing Sensitivity and Clinical Utility","status":"COMPLETED","sponsor":"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","startDate":"2019-05-01","conditions":"Lung Neoplasms, Lung Cancer, Neoplasm of Lung","enrollment":40},{"nctId":"NCT01289353","phase":"PHASE1, PHASE2","title":"Concurrent Adjuvant Carboplatin and Accelerated Radiotherapy for Triple Negative Breast Cancer","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2009-03-06","conditions":"Breast Cancer","enrollment":92},{"nctId":"NCT03364907","phase":"","title":"Clinical Pharmacology of Platinum-based Hyperthermic Intraperitoneal Chemotherapy","status":"COMPLETED","sponsor":"Radboud University Medical Center","startDate":"2018-03-01","conditions":"Peritoneal Carcinomatosis","enrollment":20},{"nctId":"NCT02078531","phase":"","title":"A Prospective Study on Effect of Systemic Adjuvant Therapy on Cognitive and Brain Function of Breast Cancer Patients","status":"UNKNOWN","sponsor":"National University Hospital, Singapore","startDate":"2014-10-29","conditions":"Breast Cancer","enrollment":130}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":360,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Adjuvant systemic chemotherapy","genericName":"Adjuvant systemic chemotherapy","companyName":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","companyId":"cancer-institute-and-hospital-chinese-academy-of-medical-sciences","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Adjuvant systemic chemotherapy is used to treat various types of cancer, including breast cancer, peritoneal carcinomatosis, colorectal cancer metastatic, stage III ovarian cancer, and stage IV ovarian cancer. The exact mechanism of adjuvant systemic chemotherapy is unknown, but it is often administered in conjunction with other treatments such as radiation therapy.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}